The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials
Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of the first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for thera...
Saved in:
| Published in | Chemical Society reviews Vol. 46; no. 19; pp. 5771 - 584 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
02.10.2017
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Summary: | Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of the first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for therapeutic design. Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anti-cancer agents that serve as alternatives to cisplatin and its derivertives. Ruthenium(
iii
) complexes have successfully been used in clinical research and their mechanisms of anticancer action have been reported in large volumes over the past few decades. Ruthenium(
ii
) complexes have also attracted significant attention as anticancer candidates; however, only a few of them have been reported comprehensively. In this review, we discuss the development of ruthenium(
ii
) complexes as anticancer candidates and biocatalysts, including arene ruthenium complexes, polypyridyl ruthenium complexes, and ruthenium nanomaterial complexes. This review focuses on the likely mechanisms of action of ruthenium(
ii
)-based anticancer drugs and the relationship between their chemical structures and biological properties. This review also highlights the catalytic activity and the photoinduced activation of ruthenium(
ii
) complexes, their targeted delivery, and their activity in nanomaterial systems.
This review covers ruthenium(
ii
) complexes as anticancer drugs in single molecules and nanomaterials and includes targets, mechanisms, SAR, PDT and nano-systems. |
|---|---|
| Bibliography: | Pranav Gupta received his Bachelor's degree in Pharmacy from Gurukul University and Master's degree in Pharmacology from St. John's University. He has worked as a graduate student researcher at St. Johns' University and has been a STEM mentor with the New York Academy of Sciences. He has published original research articles and invited reviews and book chapters in peer reviewed journals. Most recently, he has been working on developing novel inhibitors to overcome chemotherapeutic multidrug resistance under Dr Zhe-Sheng Chen. Zhe-Sheng Chen received his MS degree from Sun Yat-Sen University and PhD from Kagoshima University. He had postdoctoral training at Fox Chase Cancer Center. He joined St. John's University in 2004 as an assistant professor. He is now a full professor and the director of the Institute for Biotechnology. He is the editor-in-chief of the Journal of Cancer Research Updates, and New Developments on Chemistry, an editor of the African Journal of Pharmacy and Pharmacology, an editorial board member of 26 journals and a reviewer of ∼190 journals. He is an Ad-hoc reviewer of grants from NIH, New Zealand, Poland, China, Hungary, Netherlands, Canada, etc. He has established research projects to study ABC transporters and MDR. Liangnian Ji was elected as a member of the Chinese Academy of Sciences in 2003. Prof. Ji is actively involved in bioinorganic chemistry research. He has designed and synthesized over 600 new coordination compounds. The results have been published in over 700 research papers, 3 monographs and 15 Chinese invention patents. Prof. Ji has been invited to be an organizing committee or advisory committee member in more than 10 international conferences or symposia on bioinorganic chemistry. He is also on the editorial board or an advisory member for 8 international or national chemical journals. Hui Chao received his PhD degree from Sun Yat-Sen University in 2000 under the guidance of Prof. Liangnian Ji. Subsequently, he joined the faculty at Sun Yat-Sen University. During 2000-2003, he attended Hong Kong University of Science and Technology each year as a short-term visiting scholar. In 2004-2005, he conducted postdoctoral work with Prof. F. A. Cotton at Texas A&M University. He was promoted as a full professor in Sun Yat-Sen University in 2007. He is the author of over 180 peer reviewed publications and 4 book chapters. His current research interest is focused on metal-based anticancer complexes and bioimaging agents. Yanglu Chen graduated from Princeton University in 2017 with a Bachelor's degree in Chemistry. She has also conducted research at Fox Chase Cancer Center, St. John's University, the National Institutes of Health, University of Melbourne, and Rockefeller University, with interests ranging from immunology to genomics to nanomedicine. Most recently, she has used ultrafast spectroscopy to study photo-induced nanotheranostics under Professor Gregory Scholes. Leli Zeng received his MS degree in 2013 from XiangTan University and he worked under the supervision of Prof. Hui Chao from 2013 to 2017 at Sun Yat-Sen University, where he received his PhD degree in June 2017. During 2016-2017, he conducted a one-year study on multidrug resistance under the guidance of Prof. Zhe-Sheng Chen at St. John's University. His primary work is focused on the design of ruthenium-based cancer drugs and nanodrugs, as well as the study of drug resistance. Enju Wang received her PhD degree from ETH-Zurich in 1989 under the guidance of the later Prof. Simon in Analytical Chemistry. She joined Kagoshima University as a Research associate before her post-doctoral research in the University of Michigan with Dr Meyerhoff in 1992. She then joined the faculty at St. John's University in 1993 as an assistant professor and become full professor in 2005. She is the author of over 30 peer reviewed publications and 3 book chapters. Her current research interest is focused on developing Os/Ru-complex based optical sensors for Heparin and DNA polyanion sensing and detection. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ISSN: | 0306-0012 1460-4744 1460-4744 |
| DOI: | 10.1039/c7cs00195a |